ReviewCurrent pharmaceutical design2016
The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory.
Review in Current pharmaceutical design, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies.International journal of molecular sciences · 2020Pooled it
- Modulation of the endocannabinoid system reduces inflammatory signalling in canine mammary carcinoma cells.Veterinary record open · 2026Article
- Benzo[International journal of molecular sciences · 2025Article
- Brief exposure to (-) THC affects zebrafish embryonic locomotion with effects that persist into the next generation.Scientific reports · 2025Article
- The Impact of Potent Addictive Substances on Angiogenic Behavior: A Comprehensive Review.Current neuropharmacology · 2025Review
- From bench to bedside: the application of cannabidiol in glioma.Journal of translational medicine · 2024Review
- Article
- Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy.International journal of molecular sciences · 2024Review
- Cytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells.Frontiers in pharmacology · 2024Article
- In Vitro and In Vivo Anti-Inflammatory Effects of Cannabidiol Isolated from Novel Hemp (Molecules (Basel, Switzerland) · 2023Article
- Rational Design, Synthesis, and Evaluation of Fluorescent CBPharmaceuticals (Basel, Switzerland) · 2023Review
- Could cannabinoids provide a new hope for ovarian cancer patients?Pharmacology research & perspectives · 2023Review
- Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[International journal of molecular sciences · 2023Article
- Cannabinoids as Prospective Anti-Cancer Drugs: Mechanism of Action in Healthy and Cancer Cells.Advances in experimental medicine and biology · 2023Article
- Review
- Review
- Comparison of the in vitro Anti-Inflammatory Effect of Cannabidiol to Dexamethasone.Clinical, cosmetic and investigational dermatology · 2022Article
- Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders.Molecules (Basel, Switzerland) · 2021Review
- Review
- Can Cannabidiol Affect the Efficacy of Chemotherapy and Epigenetic Treatments in Cancer?Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells. In recent years, there has been a growing body of evidence for the use of synthetic and natural cannabinoids as potential anticancer agents. For instance, the CB1 and CB2 receptors are assumed to play an important role inside the endocannabinoid system. These receptors are abundantly expressed in the brain and fatty tissue of the human body. Despite recent developments in molecular biology, there is still a lack of knowledge about the distribution of CB1 and CB2 receptors in the human kidney and their role in kidney cancer. To address this gap, we explore and demonstrate the role of the endocannabinoid system in renal cell carcinoma (RCC). In this brief overview, we elucidate the therapeutic aspects of the endocannabinoid system for various cancers and explain how this system can be used for treating kidney cancer. Overall, this review provides new insights into cannabinoids' mechanisms of action in both in vivo and in vitro models, and focuses on recent discoveries in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.